During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Giuseppe Gritti, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked, Does polatuzumab vedotin, venetoclax, and rituximab combined enhance tumor responses in relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Does polatuzumab vedotin, venetoclax, and rituximab combined enhance tumor responses in R/R DLBCL?
Does polatuzumab vedotin, venetoclax, and rituximab combined enhance tumor responses in R/R DLBCL?
In this video, Gritti discusses the data from a study evaluating polatuzumab vedotin, venetoclax, and rituximab combined treatment in patients with R/R DLBCL.
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox